Non-motor symptoms in Huntington’s disease: a comparative study with Parkinson’s disease

go back to reference Bates GP (2005) The molecular genetics of Huntington disease—a history. Nat Rev Genet 6:766–773CrossRefPubMed Bates GP (2005) The molecular genetics of Huntington disease—a history. Nat Rev Genet 6:766–773CrossRefPubMed

go back to reference Walker FO (2007) Huntington’s disease. Lancet 369:218–228CrossRef Walker FO (2007) Huntington’s disease. Lancet 369:218–228CrossRef

go back to reference Graveland GA, Williams RS, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science 227:770–773CrossRefPubMed Graveland GA, Williams RS, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science 227:770–773CrossRefPubMed

go back to reference Rüb U, Seidel K, Heinsen H, Vonsattel JP, den Dunnen WF, Korf HW (2016) Huntington’s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol 26:726–740CrossRefPubMed Rüb U, Seidel K, Heinsen H, Vonsattel JP, den Dunnen WF, Korf HW (2016) Huntington’s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol 26:726–740CrossRefPubMed

go back to reference Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, Przuntek H, Agelink MW (2002) Autonomic nervous system function in Huntington’s disease. J Neurol Neurosurg Psychiatry 72:726–731CrossRefPubMedPubMedCentral Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, Przuntek H, Agelink MW (2002) Autonomic nervous system function in Huntington’s disease. J Neurol Neurosurg Psychiatry 72:726–731CrossRefPubMedPubMedCentral

go back to reference Mielcarek M (2015) Huntington’s disease is a multi-system disorder. Rare Dis 3:e1058464CrossRefPubMedPubMedCentral Mielcarek M (2015) Huntington’s disease is a multi-system disorder. Rare Dis 3:e1058464CrossRefPubMedPubMedCentral

go back to reference Stephen CD, Hung J, Schifitto G, Hersch SM, Rosas HD (2018) Electrocardiogram abnormalities suggest aberrant cardiac conduction in Huntington’s disease. Mov Disord Clin Pract 5:306–311CrossRefPubMedPubMedCentral Stephen CD, Hung J, Schifitto G, Hersch SM, Rosas HD (2018) Electrocardiogram abnormalities suggest aberrant cardiac conduction in Huntington’s disease. Mov Disord Clin Pract 5:306–311CrossRefPubMedPubMedCentral

go back to reference Van der Burg JMM, Winqvist A, Aziz NA, Maat-Schieman MLC, Roos RAC, Bates GP, Brundin P, Björkqvist M, Wierup N (2011) Gastrointestinal dysfunction contributes to weight loss in Huntington’s disease mice. Neurobiol Dis 44:1–8CrossRefPubMed Van der Burg JMM, Winqvist A, Aziz NA, Maat-Schieman MLC, Roos RAC, Bates GP, Brundin P, Björkqvist M, Wierup N (2011) Gastrointestinal dysfunction contributes to weight loss in Huntington’s disease mice. Neurobiol Dis 44:1–8CrossRefPubMed

go back to reference Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ (2015) Treating the whole body in Huntington’s disease. Lancet Neurol 14:1135–1142CrossRefPubMed Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ (2015) Treating the whole body in Huntington’s disease. Lancet Neurol 14:1135–1142CrossRefPubMed

go back to reference Stuwe SH, Goetze O, Lukas C, Klotz P, Hoffmann R, Banasch M, Orth M, Schmidt WE, Gold R, Saft C (2013) Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology 80:743–746CrossRefPubMed Stuwe SH, Goetze O, Lukas C, Klotz P, Hoffmann R, Banasch M, Orth M, Schmidt WE, Gold R, Saft C (2013) Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology 80:743–746CrossRefPubMed

go back to reference Chaudhuri KR, Sauerbier A, Rojo JM, Sethi K, Schapira AHV, Brown RG, Antonini A, Stocchi F, Odin P, Bhattacharya K, Tsuboi Y, Abe K, Rizos A, Rodriguez-Blazquez C, Martinez-Martin P (2015) The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system. Park Relat Disord 21:287–291CrossRef Chaudhuri KR, Sauerbier A, Rojo JM, Sethi K, Schapira AHV, Brown RG, Antonini A, Stocchi F, Odin P, Bhattacharya K, Tsuboi Y, Abe K, Rizos A, Rodriguez-Blazquez C, Martinez-Martin P (2015) The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system. Park Relat Disord 21:287–291CrossRef

go back to reference Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923CrossRefPubMed Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923CrossRefPubMed

go back to reference Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11:136–142CrossRef Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11:136–142CrossRef

go back to reference Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRef Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRef

go back to reference Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Agarwal P, Athar S, Bordelan Y, Bronte-Stewart HM, Camicioli R, Chou K, Cole W, Dalvi A, Delgado H, Diamond A, Dick JP, Duda J, Elble RJ, Evans C, Evidente VG, Fernandez HH, Fox S, Friedman JH, Fross RD, Gallagher D, Goetz CG, Hall D, Hermanowicz N, Hinson V, Horn S, Hurtig H, Kang UJ, Kleiner-Fisman G, Klepitskaya O, Kompoliti K, Lai EC, Leehey ML, Leroi I, Lyons KE, McClain T, Metzer SW, Miyasaki J, Morgan JC, Nance M, Nemeth J, Pahwa R, Parashos SA, Schneider JSJS, Schrag A, Sethi K, Shulman LM, Siderowf A, Silverdale M, Simuni T, Stacy M, Stern MB, Stewart RM, Sullivan K, Swope DM, Wadia PM, Walker RW, Walker R, Weiner WJ, Wiener J, Wilkinson J, Wojcieszek JM, Wolfrath S, Wooten F, Wu A, Zesiewicz TA, Zweig RM (2008) Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23:2129–2170. https://doi.org/10.1002/mds.22340 CrossRefPubMed Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Agarwal P, Athar S, Bordelan Y, Bronte-Stewart HM, Camicioli R, Chou K, Cole W, Dalvi A, Delgado H, Diamond A, Dick JP, Duda J, Elble RJ, Evans C, Evidente VG, Fernandez HH, Fox S, Friedman JH, Fross RD, Gallagher D, Goetz CG, Hall D, Hermanowicz N, Hinson V, Horn S, Hurtig H, Kang UJ, Kleiner-Fisman G, Klepitskaya O, Kompoliti K, Lai EC, Leehey ML, Leroi I, Lyons KE, McClain T, Metzer SW, Miyasaki J, Morgan JC, Nance M, Nemeth J, Pahwa R, Parashos SA, Schneider JSJS, Schrag A, Sethi K, Shulman LM, Siderowf A, Silverdale M, Simuni T, Stacy M, Stern MB, Stewart RM, Sullivan K, Swope DM, Wadia PM, Walker RW, Walker R, Weiner WJ, Wiener J, Wilkinson J, Wojcieszek JM, Wolfrath S, Wooten F, Wu A, Zesiewicz TA, Zweig RM (2008) Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23:2129–2170. https://​doi.​org/​10.​1002/​mds.​22340 CrossRefPubMed

go back to reference Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29:1–1CrossRefPubMed Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29:1–1CrossRefPubMed

go back to reference Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–649CrossRefPubMed Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–649CrossRefPubMed

go back to reference Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629CrossRefPubMed Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629CrossRefPubMed

go back to reference Sauerbier A, Chaudhuri KR (2014) Non-motor symptoms: the core of multi-morbid Parkinson’s disease. Br J Hosp Med 75:18–24CrossRef Sauerbier A, Chaudhuri KR (2014) Non-motor symptoms: the core of multi-morbid Parkinson’s disease. Br J Hosp Med 75:18–24CrossRef

go back to reference Aziz NA, Swaab DF, Pijl H, Roos RAC (2007) Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington’s Disease: clinical consequences and therapeutic implications. Rev Neurosci 18:223–252CrossRefPubMed Aziz NA, Swaab DF, Pijl H, Roos RAC (2007) Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington’s Disease: clinical consequences and therapeutic implications. Rev Neurosci 18:223–252CrossRefPubMed

go back to reference Poewe W (2008) Non-motor symptoms in Parkinson’s disease. Eur J Neurol 15(Suppl 1):14–20CrossRefPubMed Poewe W (2008) Non-motor symptoms in Parkinson’s disease. Eur J Neurol 15(Suppl 1):14–20CrossRefPubMed

go back to reference Heemskerk A-W, Roos RAC (2012) Aspiration pneumonia and death in Huntington’s disease. PLoS Curr 4:RRN1293CrossRefPubMedPubMedCentral Heemskerk A-W, Roos RAC (2012) Aspiration pneumonia and death in Huntington’s disease. PLoS Curr 4:RRN1293CrossRefPubMedPubMedCentral

go back to reference Heemskerk A-W, Roos RAC (2011) Dysphagia in Huntington’s disease: a review. Dysphagia 26:62–66CrossRefPubMed Heemskerk A-W, Roos RAC (2011) Dysphagia in Huntington’s disease: a review. Dysphagia 26:62–66CrossRefPubMed

go back to reference Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF (2015) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 14:625–639CrossRefPubMed Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF (2015) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 14:625–639CrossRefPubMed

go back to reference Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP (2009) Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington’s disease. PLoS One 4:e8025CrossRefPubMedPubMedCentral Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP (2009) Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington’s disease. PLoS One 4:e8025CrossRefPubMedPubMedCentral

go back to reference Ondo WG, Tintner R, Thomas M, Jankovic J (2002) Tetrabenazine treatment for Huntington’s disease-associated chorea. Clin Neuropharmacol 25:300–302CrossRefPubMed Ondo WG, Tintner R, Thomas M, Jankovic J (2002) Tetrabenazine treatment for Huntington’s disease-associated chorea. Clin Neuropharmacol 25:300–302CrossRefPubMed

go back to reference De Hert M, Dockx L, Bernagie C, Peuskens B, Sweers K, Leucht S, Tack J, Van de Straete S, Wampers M, Peuskens J (2011) Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. BMC Gastroenterol 11:17CrossRefPubMedPubMedCentral De Hert M, Dockx L, Bernagie C, Peuskens B, Sweers K, Leucht S, Tack J, Van de Straete S, Wampers M, Peuskens J (2011) Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. BMC Gastroenterol 11:17CrossRefPubMedPubMedCentral

go back to reference Stocchi F, Torti M (2017) Constipation in Parkinson’s disease. Int Rev Neurobiol 134:811–826CrossRefPubMed Stocchi F, Torti M (2017) Constipation in Parkinson’s disease. Int Rev Neurobiol 134:811–826CrossRefPubMed

go back to reference Perez-Lloret S, Rascol O (2018) Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm 125:1237–1250CrossRefPubMed Perez-Lloret S, Rascol O (2018) Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm 125:1237–1250CrossRefPubMed

go back to reference Nordin S, Paulsen JS, Murphy C (1995) Sensory- and memory-mediated olfactory dysfunction in Huntington’s disease. J Int Neuropsychol Soc 1:281–290CrossRefPubMed Nordin S, Paulsen JS, Murphy C (1995) Sensory- and memory-mediated olfactory dysfunction in Huntington’s disease. J Int Neuropsychol Soc 1:281–290CrossRefPubMed

go back to reference Barrios FA, Gonzalez L, Favila R, Alonso ME, Salgado PM, Diaz R, Fernandez-Ruiz J (2007) Olfaction and neurodegeneration in HD. Neuroreport 18:73–76CrossRefPubMed Barrios FA, Gonzalez L, Favila R, Alonso ME, Salgado PM, Diaz R, Fernandez-Ruiz J (2007) Olfaction and neurodegeneration in HD. Neuroreport 18:73–76CrossRefPubMed

go back to reference Kandasamy M, Rosskopf M, Wagner K, Klein B, Couillard-Despres S, Reitsamer HA, Stephan M, Nguyen HP, Riess O, Bogdahn U, Winkler J, von Horsten S, Aigner L (2015) Reduction in subventricular zone-derived olfactory bulb neurogenesis in a rat model of Huntington’s disease is accompanied by striatal invasion of neuroblasts. PLoS One 10:e0116069CrossRefPubMedPubMedCentral Kandasamy M, Rosskopf M, Wagner K, Klein B, Couillard-Despres S, Reitsamer HA, Stephan M, Nguyen HP, Riess O, Bogdahn U, Winkler J, von Horsten S, Aigner L (2015) Reduction in subventricular zone-derived olfactory bulb neurogenesis in a rat model of Huntington’s disease is accompanied by striatal invasion of neuroblasts. PLoS One 10:e0116069CrossRefPubMedPubMedCentral

go back to reference Aziz NA, Anguelova GV, Marinus J, Van Dijk JG, Roos RAC (2010) Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington’s disease. Eur J Neurol 17:1068–1074CrossRefPubMed Aziz NA, Anguelova GV, Marinus J, Van Dijk JG, Roos RAC (2010) Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington’s disease. Eur J Neurol 17:1068–1074CrossRefPubMed

go back to reference Kolenc M, Moharic M, Kobal J, Podnar S (2014) Bladder dysfunction in presymptomatic gene carriers and patients with Huntington’s disease. J Neurol 261:2360–2369CrossRefPubMed Kolenc M, Moharic M, Kobal J, Podnar S (2014) Bladder dysfunction in presymptomatic gene carriers and patients with Huntington’s disease. J Neurol 261:2360–2369CrossRefPubMed

go back to reference Rana AQ, Vaid H, Akhter MR, Awan NY, Fattah A, Cader MH, Hafez K, Rana MA, Yousuf MS (2014) Prevalence of nocturia in Parkinson’s disease patients from various ethnicities. Neurol Res 36:234–238CrossRefPubMed Rana AQ, Vaid H, Akhter MR, Awan NY, Fattah A, Cader MH, Hafez K, Rana MA, Yousuf MS (2014) Prevalence of nocturia in Parkinson’s disease patients from various ethnicities. Neurol Res 36:234–238CrossRefPubMed

go back to reference Vaughan CP, Bliwise DL (2018) Sleep and nocturia in older adults. Sleep Med Clin 13:107–116CrossRefPubMed Vaughan CP, Bliwise DL (2018) Sleep and nocturia in older adults. Sleep Med Clin 13:107–116CrossRefPubMed

go back to reference Dumas EM, van den Bogaard SJA, Middelkoop HAM, Roos RAC (2013) A review of cognition in Huntington’s disease. Front Biosci (Schol Ed) 5:1–18CrossRef Dumas EM, van den Bogaard SJA, Middelkoop HAM, Roos RAC (2013) A review of cognition in Huntington’s disease. Front Biosci (Schol Ed) 5:1–18CrossRef

go back to reference Montoya A, Pelletier M, Menear M, Duplessis E (2006) Episodic memory impairment in Huntington’ s disease: a meta-analysis. Neuropsychologia 44:1984–1994CrossRefPubMed Montoya A, Pelletier M, Menear M, Duplessis E (2006) Episodic memory impairment in Huntington’ s disease: a meta-analysis. Neuropsychologia 44:1984–1994CrossRefPubMed

go back to reference Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB (2010) Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY. PLoS Curr 2:RRN1184PubMed Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB (2010) Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY. PLoS Curr 2:RRN1184PubMed

go back to reference Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R (2012) A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 29:639–658PubMed Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R (2012) A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 29:639–658PubMed

go back to reference Naarding P, Janzing JGE, Eling P, van der Werf S, Kremer B (2009) Apathy is not depression in Huntington’s disease. J Neuropsychiatry Clin Neurosci 21:266–270CrossRefPubMed Naarding P, Janzing JGE, Eling P, van der Werf S, Kremer B (2009) Apathy is not depression in Huntington’s disease. J Neuropsychiatry Clin Neurosci 21:266–270CrossRefPubMed

go back to reference Reedeker N, Bouwens JA, van Duijn E, Giltay EJ, Roos RAC, van der Mast RC (2011) Incidence, course, and predictors of apathy in Huntington’s disease: a two-year prospective study. J Neuropsychiatry Clin Neurosci 23:434–441CrossRefPubMed Reedeker N, Bouwens JA, van Duijn E, Giltay EJ, Roos RAC, van der Mast RC (2011) Incidence, course, and predictors of apathy in Huntington’s disease: a two-year prospective study. J Neuropsychiatry Clin Neurosci 23:434–441CrossRefPubMed

go back to reference van Duijn E, Reedeker N, Giltay EJ, Eindhoven D, Roos RAC, van der Mast RC (2014) Course of irritability, depression and apathy in Huntington’s disease in relation to motor symptoms during a two-year follow-up period. Neurodegener Dis 13:9–16PubMed van Duijn E, Reedeker N, Giltay EJ, Eindhoven D, Roos RAC, van der Mast RC (2014) Course of irritability, depression and apathy in Huntington’s disease in relation to motor symptoms during a two-year follow-up period. Neurodegener Dis 13:9–16PubMed

go back to reference van Duijn E, Reedeker N, Giltay EJ, Roos RAC, van der Mast RC (2010) Correlates of apathy in Huntington’s disease. J Neuropsychiatry Clin Neurosci 22:287–294CrossRefPubMed van Duijn E, Reedeker N, Giltay EJ, Roos RAC, van der Mast RC (2010) Correlates of apathy in Huntington’s disease. J Neuropsychiatry Clin Neurosci 22:287–294CrossRefPubMed

go back to reference Martinez-Horta S, Perez-Perez J, Sampedro F, Pagonabarraga J, Horta-Barba A, Carceller-Sindreu M, Gomez-Anson B, Lozano-Martinez GA, Lopez-Mora DA, Camacho V, Fernandez-Leon A, Carrio I, Kulisevsky J (2018) Structural and metabolic brain correlates of apathy in Huntington’s disease. Mov Disord 33(7):1151–1159CrossRefPubMed Martinez-Horta S, Perez-Perez J, Sampedro F, Pagonabarraga J, Horta-Barba A, Carceller-Sindreu M, Gomez-Anson B, Lozano-Martinez GA, Lopez-Mora DA, Camacho V, Fernandez-Leon A, Carrio I, Kulisevsky J (2018) Structural and metabolic brain correlates of apathy in Huntington’s disease. Mov Disord 33(7):1151–1159CrossRefPubMed

go back to reference Sousa M, Moreira F, Jesus-Ribeiro J, Marques I, Cunha F, Canário N, Freire A, Januário C (2018) Apathy profile in Parkinson’s and Huntington’s disease: a comparative cross-sectional study. Eur Neurol 79:13–20CrossRefPubMed Sousa M, Moreira F, Jesus-Ribeiro J, Marques I, Cunha F, Canário N, Freire A, Januário C (2018) Apathy profile in Parkinson’s and Huntington’s disease: a comparative cross-sectional study. Eur Neurol 79:13–20CrossRefPubMed

go back to reference Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L (2009) Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 24:2391–2397CrossRefPubMed Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L (2009) Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 24:2391–2397CrossRefPubMed

go back to reference Krishnamoorthy A, Craufurd D (2011) Treatment of apathy in Huntington’s disease and other movement disorders. Curr Treat Options Neurol 13:508–519CrossRefPubMed Krishnamoorthy A, Craufurd D (2011) Treatment of apathy in Huntington’s disease and other movement disorders. Curr Treat Options Neurol 13:508–519CrossRefPubMed

go back to reference Ory-Magne F, Corvol J-C, Azulay J-P, Bonnet A-M, Brefel-Courbon C, Damier P, Dellapina E, Destee A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82:300–307CrossRefPubMed Ory-Magne F, Corvol J-C, Azulay J-P, Bonnet A-M, Brefel-Courbon C, Damier P, Dellapina E, Destee A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82:300–307CrossRefPubMed

go back to reference van Duijn E, Kingma EM, van der Mast RC (2007) Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci 19:441–448CrossRefPubMed van Duijn E, Kingma EM, van der Mast RC (2007) Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci 19:441–448CrossRefPubMed

go back to reference Paoli RA, Botturi A, Ciammola A, Silani V, Prunas C, Lucchiari C, Zugno E, Caletti E (2017) Neuropsychiatric burden in Huntington’s disease. Brain Sci 7:67CrossRefPubMedCentral Paoli RA, Botturi A, Ciammola A, Silani V, Prunas C, Lucchiari C, Zugno E, Caletti E (2017) Neuropsychiatric burden in Huntington’s disease. Brain Sci 7:67CrossRefPubMedCentral

go back to reference Thompson JC, Snowden JS, Craufurd D, Neary D (2002) Behavior in Huntington’s disease: dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci 14:37–43CrossRefPubMed Thompson JC, Snowden JS, Craufurd D, Neary D (2002) Behavior in Huntington’s disease: dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci 14:37–43CrossRefPubMed

go back to reference Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R, McDowell B, Turner B (2005) Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci 17:496–502CrossRefPubMed Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R, McDowell B, Turner B (2005) Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci 17:496–502CrossRefPubMed

go back to reference Paulsen JS, Hoth KF, Nehl C, Stierman L (2005) Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry 162:725–731CrossRefPubMed Paulsen JS, Hoth KF, Nehl C, Stierman L (2005) Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry 162:725–731CrossRefPubMed

go back to reference Hubers AAM, van Duijn E, Roos RAC, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ (2013) Suicidal ideation in a European Huntington’s disease population. J Affect Disord 151:248–258CrossRefPubMed Hubers AAM, van Duijn E, Roos RAC, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ (2013) Suicidal ideation in a European Huntington’s disease population. J Affect Disord 151:248–258CrossRefPubMed

go back to reference Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I, IsHak WW (2018) NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease. Transl Psychiatry 8:117CrossRefPubMedPubMedCentral Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I, IsHak WW (2018) NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease. Transl Psychiatry 8:117CrossRefPubMedPubMedCentral

go back to reference Mendez MF (1994) Huntington’s disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med 24:189–208CrossRefPubMed Mendez MF (1994) Huntington’s disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med 24:189–208CrossRefPubMed

go back to reference van Duijn E, Craufurd D, Hubers AAM, Giltay EJ, Bonelli R, Rickards H, Anderson KE, van Walsem MR, van der Mast RC, Orth M, Landwehrmeyer GB (2014) Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 85:1411–1418CrossRefPubMed van Duijn E, Craufurd D, Hubers AAM, Giltay EJ, Bonelli R, Rickards H, Anderson KE, van Walsem MR, van der Mast RC, Orth M, Landwehrmeyer GB (2014) Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 85:1411–1418CrossRefPubMed

go back to reference Register SL, Ruano OL, Sanchez DL, Catalano G, Catalano MC (2017) Hallucinations associated with topiramate therapy: a case report and review of the literature. Curr Drug Saf 12:193–197CrossRefPubMed Register SL, Ruano OL, Sanchez DL, Catalano G, Catalano MC (2017) Hallucinations associated with topiramate therapy: a case report and review of the literature. Curr Drug Saf 12:193–197CrossRefPubMed

go back to reference Nakamura M, Koo J (2016) Drug-induced tactile hallucinations beyond recreational drugs. Am J Clin Dermatol 17:643–652CrossRefPubMed Nakamura M, Koo J (2016) Drug-induced tactile hallucinations beyond recreational drugs. Am J Clin Dermatol 17:643–652CrossRefPubMed

go back to reference Diederen KMJ, Neggers SFW, de Weijer AD, van Lutterveld R, Daalman K, Eickhoff SB, Clos M, Kahn RS, Sommer IEC (2013) Aberrant resting-state connectivity in non-psychotic individuals with auditory hallucinations. Psychol Med 43:1685–1696CrossRefPubMed Diederen KMJ, Neggers SFW, de Weijer AD, van Lutterveld R, Daalman K, Eickhoff SB, Clos M, Kahn RS, Sommer IEC (2013) Aberrant resting-state connectivity in non-psychotic individuals with auditory hallucinations. Psychol Med 43:1685–1696CrossRefPubMed

go back to reference Dewhurst K, Oliver JE, McKnight AL (1970) Socio-psychiatric consequences of Huntington’s disease. Br J Psychiatry 116:255–258CrossRefPubMed Dewhurst K, Oliver JE, McKnight AL (1970) Socio-psychiatric consequences of Huntington’s disease. Br J Psychiatry 116:255–258CrossRefPubMed

go back to reference Fedoroff JP, Peyser C, Franz ML, Folstein SE (1994) Sexual disorders in Huntington’s disease. J Neuropsychiatry Clin Neurosci 6:147–153CrossRefPubMed Fedoroff JP, Peyser C, Franz ML, Folstein SE (1994) Sexual disorders in Huntington’s disease. J Neuropsychiatry Clin Neurosci 6:147–153CrossRefPubMed

go back to reference Reininghaus E, Lackner N (2015) Relationship satisfaction and sexuality in Huntington’s disease. Handb Clin Neurol 130:325–334CrossRefPubMed Reininghaus E, Lackner N (2015) Relationship satisfaction and sexuality in Huntington’s disease. Handb Clin Neurol 130:325–334CrossRefPubMed

go back to reference Kolenc M, Kobal J, Podnar S (2017) Female sexual dysfunction in presymptomatic mutation carriers and patients with Huntington’s disease. J Huntingtons Dis 6:105–113CrossRefPubMed Kolenc M, Kobal J, Podnar S (2017) Female sexual dysfunction in presymptomatic mutation carriers and patients with Huntington’s disease. J Huntingtons Dis 6:105–113CrossRefPubMed

go back to reference Sharma KR, Romano JG, Ayyar DR, Rotta FT, Facca A, Sanchez-Ramos J (1999) Sympathetic skin response and heart rate variability in patients with Huntington disease. Arch Neurol 56:1248–1252CrossRefPubMed Sharma KR, Romano JG, Ayyar DR, Rotta FT, Facca A, Sanchez-Ramos J (1999) Sympathetic skin response and heart rate variability in patients with Huntington disease. Arch Neurol 56:1248–1252CrossRefPubMed

go back to reference van der Burg JMM, Björkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol 8:765–774CrossRefPubMed van der Burg JMM, Björkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol 8:765–774CrossRefPubMed

go back to reference Grimbergen YAM, Knol MJ, Bloem BR, Kremer BPH, Roos RAC, Munneke M (2008) Falls and gait disturbances in Huntington’s disease. Mov Disord 23:970–976CrossRefPubMed Grimbergen YAM, Knol MJ, Bloem BR, Kremer BPH, Roos RAC, Munneke M (2008) Falls and gait disturbances in Huntington’s disease. Mov Disord 23:970–976CrossRefPubMed

go back to reference Verhaeverbeke I, Mets T (1997) Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 17:105–118CrossRefPubMed Verhaeverbeke I, Mets T (1997) Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 17:105–118CrossRefPubMed

go back to reference Hansotia P, Wall R, Berendes J (1985) Sleep disturbances and severity of Huntington’s disease. Neurology 35:1672–1674CrossRefPubMed Hansotia P, Wall R, Berendes J (1985) Sleep disturbances and severity of Huntington’s disease. Neurology 35:1672–1674CrossRefPubMed

go back to reference Arnulf I, Nielsen J, Lohmann E, Schiefer J, Wild E, Jennum P, Konofal E, Walker M, Oudiette D, Tabrizi S, Durr A (2008) Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 65:482–488CrossRefPubMed Arnulf I, Nielsen J, Lohmann E, Schiefer J, Wild E, Jennum P, Konofal E, Walker M, Oudiette D, Tabrizi S, Durr A (2008) Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 65:482–488CrossRefPubMed

go back to reference Silvestri R, Raffaele M, De Domenico P, Tisano A, Mento G, Casella C, Tripoli MC, Serra S, Di Perri R (1995) Sleep features in Tourette’s syndrome, neuroacanthocytosis and Huntington’s chorea. Neurophysiol Clin Neurophysiol 25:66–77CrossRef Silvestri R, Raffaele M, De Domenico P, Tisano A, Mento G, Casella C, Tripoli MC, Serra S, Di Perri R (1995) Sleep features in Tourette’s syndrome, neuroacanthocytosis and Huntington’s chorea. Neurophysiol Clin Neurophysiol 25:66–77CrossRef

go back to reference Varda E, Demetriou CA, Heraclides A, Christou YP, Zamba-Papanicolaou E (2016) Quality of life of Cypriot patients suffering with Huntington’s disease. PLoS Curr 8:ecurrentsPubMedPubMedCentral Varda E, Demetriou CA, Heraclides A, Christou YP, Zamba-Papanicolaou E (2016) Quality of life of Cypriot patients suffering with Huntington’s disease. PLoS Curr 8:ecurrentsPubMedPubMedCentral

go back to reference Johnson MO, Frank S, Mendlik M, Casarett D (2018) Utilization of hospice services in a population of patients with Huntington’s disease. J Pain Symptom Manage 55:440–443CrossRefPubMed Johnson MO, Frank S, Mendlik M, Casarett D (2018) Utilization of hospice services in a population of patients with Huntington’s disease. J Pain Symptom Manage 55:440–443CrossRefPubMed

go back to reference Nance MA, Sanders G (1996) Characteristics of individuals with Huntington disease in long-term care. Mov Disord 11:542–548CrossRefPubMed Nance MA, Sanders G (1996) Characteristics of individuals with Huntington disease in long-term care. Mov Disord 11:542–548CrossRefPubMed

go back to reference Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, Pettengill FK, Bird ED (1991) Factors associated with slow progression in Huntington’s disease. Arch Neurol 48:800–804CrossRefPubMed Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, Pettengill FK, Bird ED (1991) Factors associated with slow progression in Huntington’s disease. Arch Neurol 48:800–804CrossRefPubMed

go back to reference Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S, Miljic D, Milic N, Glodic J, Dieguez C, Casanueva FF, Kostic V (2004) Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington’s disease. Eur J Endocrinol 151:451–455CrossRefPubMed Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S, Miljic D, Milic N, Glodic J, Dieguez C, Casanueva FF, Kostic V (2004) Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington’s disease. Eur J Endocrinol 151:451–455CrossRefPubMed

go back to reference Aziz NA, van der Burg JMM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RAC (2008) Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71:1506–1513CrossRefPubMed Aziz NA, van der Burg JMM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RAC (2008) Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71:1506–1513CrossRefPubMed

go back to reference Mahant N, McCusker EA, Byth K, Graham S (2003) Huntington’s disease: clinical correlates of disability and progression. Neurology 61:1085–1092CrossRefPubMed Mahant N, McCusker EA, Byth K, Graham S (2003) Huntington’s disease: clinical correlates of disability and progression. Neurology 61:1085–1092CrossRefPubMed

go back to reference Goodman AOG, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ, Morton AJ, Barker RA (2008) The metabolic profile of early Huntington’s disease—a combined human and transgenic mouse study. Exp Neurol 210:691–698CrossRefPubMed Goodman AOG, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ, Morton AJ, Barker RA (2008) The metabolic profile of early Huntington’s disease—a combined human and transgenic mouse study. Exp Neurol 210:691–698CrossRefPubMed

go back to reference Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay J-P, Tranchant C, Broussolle E, Morin F, Bachoud-Levi A-C, Maison P (2009) Neuroendocrine disturbances in Huntington’s disease. PLoS One 4:e4962CrossRefPubMedPubMedCentral Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay J-P, Tranchant C, Broussolle E, Morin F, Bachoud-Levi A-C, Maison P (2009) Neuroendocrine disturbances in Huntington’s disease. PLoS One 4:e4962CrossRefPubMedPubMedCentral